Table I.
Clinical characteristics of the 64 patients with DLBCL.
| Characteristics | No. of patients | Percentage (%) |
|---|---|---|
| Sex | ||
| Male | 33 | 51.6 |
| Female | 31 | 48.4 |
| Age (years) | ||
| ≤60 | 34 | 53.1 |
| >60 | 30 | 46.9 |
| B symptoms | ||
| Yes | 17 | 26.6 |
| No | 47 | 73.4 |
| Ann Arbor stage | ||
| I+II | 22 | 34.4 |
| III+IV | 42 | 65.6 |
| IPI | ||
| ≤2 | 40 | 62.5 |
| >2 | 24 | 37.5 |
| LDH | ||
| Normal | 34 | 53.1 |
| Abnormal | 30 | 46.9 |
| β2-MG | ||
| Normal | 37 | 57.8 |
| Abnormal | 27 | 42.2 |
| Nln | ||
| <2 | 14 | 21.9 |
| ≥2 | 50 | 78.1 |
| Neo | ||
| <2 | 49 | 76.6 |
| ≥2 | 15 | 23.4 |
| BMI | ||
| No | 52 | 81.2 |
| Yes | 12 | 18.8 |
| Necrosis | ||
| No | 49 | 76.6 |
| Yes | 15 | 23.4 |
DLBCL, diffuse large B-cell lymphoma; IPI, International Prognostic Index, LDH, lactate dehydrogenase; β2-MG, β2 microglobulin; Nln, number of lymph node area involvement; Neo, number of extranodal organ involvement; BMI, bone marrow involvement.